Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae
- 1 March 2019
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 63 (3) , e02048-18
Abstract
Meropenem-vaborbactam is a new agent with the potential to treat carbapenem-resistant Enterobacteriaceae (CRE) infections. We describe the in vitro activity of meropenem-vaborbactam against representative CRE genotypes and laboratory-engineered Escherichia coli isolates harboring mutant bla KPC genes associated with ceftazidime-avibactam resistance.Keywords
Funding Information
- HHS | NIH | NIH Clinical Center (K08AI114883)
- HHS | NIH | NIH Clinical Center (R21AI128338)
- HHS | NIH | NIH Clinical Center (R21AI111037)
- HHS | NIH | NIH Clinical Center (R01AI104895, R21AI123747, R21AI135522)
This publication has 30 references indexed in Scilit:
- Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused byKlebsiella pneumoniaeCarbapenemase–producingK. pneumoniaeClinical Infectious Diseases, 2018
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae InfectionsAntimicrobial Agents and Chemotherapy, 2018
- Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant EnterobacteriaceaeClinical Infectious Diseases, 2017
- Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae BacteremiaAntimicrobial Agents and Chemotherapy, 2017
- Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of LiteratureOpen Forum Infectious Diseases, 2017
- Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolateJournal of Antimicrobial Chemotherapy, 2017
- Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae InfectionsAntimicrobial Agents and Chemotherapy, 2017
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.Clinical Infectious Diseases, 2016
- Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsOpen Forum Infectious Diseases, 2015
- Carbapenem-Resistant Enterobacteriaceae: Epidemiology and PreventionClinical Infectious Diseases, 2011